Cargando…
S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway
Anemia of inflammation (AI) is clinically prevalent and greatly threatens public health. Traditional remedies have raised controversy during clinical practice, calling for alternative therapies. We have recently found that hydrogen sulfide (H(2)S) inhibits inflammatory hepcidin, the critical mediato...
Autores principales: | Wang, Minjun, Tang, Wenbo, Xin, Hong, Zhu, Yi Zhun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029915/ https://www.ncbi.nlm.nih.gov/pubmed/27649298 http://dx.doi.org/10.1371/journal.pone.0163289 |
Ejemplares similares
-
An Update on AMPK in Hydrogen Sulfide Pharmacology
por: Wang, Minjun, et al.
Publicado: (2017) -
Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity
por: Wu, J, et al.
Publicado: (2016) -
Cardioprotective Effects of a Novel Hydrogen Sulfide Agent–Controlled Release Formulation of S-Propargyl-Cysteine on Heart Failure Rats and Molecular Mechanisms
por: Huang, Chengrong, et al.
Publicado: (2013) -
Mechanism of Growth Regulation of Yeast Involving Hydrogen Sulfide From S-Propargyl-Cysteine Catalyzed by Cystathionine-γ-Lyase
por: Gu, Zhongkai, et al.
Publicado: (2021) -
A Novel Liposomal S-Propargyl-Cysteine: A Sustained Release of Hydrogen Sulfide Reducing Myocardial Fibrosis via TGF-β1/Smad Pathway
por: Tran, Ba Hieu, et al.
Publicado: (2019)